Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin in patients with metabolic dysfunction-associated steatotic liver disease
IRCT20260524069511N1Phase 2Recruiting
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rifaximin in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Ahvaz Jundishapur University of Medical Sciences. Started Jul 2026; status: recruiting.
02
Drugs
rifaximin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20260524069511N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260524069511N1.